Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 7/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634951 | 0.85 | ALDH1A1 (0.33) | ALDH1A1CYP1A2CYP2D6BCHE | |
| SCHEMBL6637251 | 0.83 | L3MBTL1 (0.40) | CA2MEN1KMT2AMAPTHTT | |
| SCHEMBL19692827 | 0.82 | ALDH1A1 (0.51) | OPRK1OPRM1CA2ALDH1A1MEN1 | |
| SCHEMBL2477823 | 0.79 | GAA (0.37) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3845344 | 0.78 | SIGMAR1 (0.40) | CA2ALDH1A1MAPTMAP4K4 | |
| SCHEMBL1043443 | 0.77 | OPRK1 (0.40) | OPRK1OPRM1CA2ALDH1A1MEN1 | |
| SCHEMBL1044325 | 0.77 | MEN1 (0.52) | CA2MEN1KMT2AMAPTBCHE | |
| SCHEMBL2018449 | 0.77 | MEN1 (0.56) | OPRK1OPRM1ALDH1A1MEN1KMT2A | |
| SCHEMBL1244793 | 0.77 | — | — | |
| SCHEMBL6638323 | 0.76 | MEN1 (0.42) | MEN1KMT2AMAPTSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | claimed |
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | claimed |
| US-6627624-B1 | Agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, | NEUROGEN CORPORATION | 2003-09-30 | — | — | US | claimed |
| WO-2019043176-A2 | HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | 4SC AG (DE) | 2019-03-07 | — | — | WO | disclosed |
| US-8969401-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2015-03-03 | — | — | US | disclosed |
| EP-1725528-B1 | SULPHONYLPYRROLES AS HDAC INHIBITORS | 4SC AG (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | ALTANA PHARMA AG (DE) | 2013-03-28 | — | — | US | disclosed |
| US-8399505-B2 | Sulfonylpyrroles | 4SC AG (DE) | 2013-03-19 | — | — | US | disclosed |
| CN-1926103-B | Sulfonyl pyrroles as HDAC inhibitors | 4SC AG | 2012-12-19 | — | — | CN | disclosed |
| CN-101268070-B | Novel sulphonylpyrroles as inhibitors of HDAC novel sulphonylpyrroles | NYCOMED GMBH | 2012-09-05 | — | — | CN | disclosed |
| US-8232297-B2 | Sulphonylpyrroles as inhibitors of HDACs novel sulphonylpyrroles | 4SC AG (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070184979-A1 | Novel sulfonylpyrroles | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007039404-A1 | NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039403-A1 | SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS | NYCOMED GMBH (DE) | 2007-04-12 | — | — | WO | disclosed |
| CN-1926103-A | Sulfonyl pyrroles as HDAC inhibitors | ALTANA PHARMA AG (DE) | 2007-03-07 | — | — | CN | disclosed |
| EP-1725528-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | Altana Pharma AG (DE) | 2006-11-29 | — | — | EP | disclosed |
| CN-1849121-A | Piperazine derivatives as bradyknin antagonist | AMGEN INC (US) | 2006-10-18 | — | — | CN | disclosed |
| WO-2005087724-A2 | SULPHONYLPYRROLES AS HDAC INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-22 | — | — | WO | disclosed |
| EP-1165557-B1 | ARYL AND HETEROARYL FUSED AMINOALKYL-IMIDAZOLE DERIVATIVES: SELECTIVE MODULATORS OF GABAa RECEPTORS | NEUROGEN CORP (US) | 2004-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070184979-A1 | Novel sulfonylpyrroles | HDAC1, HDAC4, HDAC3 | OPRK1 4090/4885OPRM1 4071/4885CA2 1671/4885 |
| US-20130079347-A1 | NOVEL SULFONYLPYRROLES | HDAC3, HDAC1, HDAC2 | OPRK1 2617/4885OPRM1 3569/4885CA2 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.